Huh? There's nothing to stockpile. The drug was manufactured awhile ago. It's available to use, but that's been the case well before this latest scare. They aren't making any new drug unless it is requested. If it has been requested, we'll know about it right away.
I think you have too much time on your hands. For someone with so many years of investment experience, you seem to be worrying an awful lot over minute details.
The market has been hot since the last mini-correction. It'll probably cool off for a few days sometime here soon, and then take off again. I expect SRPT to join the ride on the next larger market lift.
The first part is true. The second part is false. Institutional ownership is nearly the same this quarter as last. The issue is that it is much easier to control the price of a stock by shorting it and daytrading than it is by going long. Therein lies the problem with this stock.
Starfe, it really seems like this has become OCD for you. Might be time for a trip to Japan and no internet access for awhile. You're going bonkers.
I would go with September also. However, the open interest in options isn't very good, so I'm not going to play them.
If the company has legitimately hired Evercore to determine strategic options, a deal of some sort will occur. It's just a matter of when. You don't hire a firm like Evercore if you plan on keeping things status quo.
Maybe, thig. But there's never a sure thing with the FDA, and that's always been true, even before SRPT's issues with them. The CEO should have considered that. But since then, I do think he's done everything he can to get the drug as quickly as possible to the boys.
I think the reason you rarely post on these boards is probably because you just created your id three days ago. So I'm not entirely sure how sincere and legit your post is.
I have mixed feelings about the CEO and how he has conducted himself in certain ways. I'm not fond of the hand-over-fist option grants (coupled with the lack of any open market purchases) and the constant internal drama that clearly exists at the company. I'm also frustrated that the process is moving at a snail's pace and think that other boys should have been enrolled in an open trial after the 48-week data came out. It would have solidified our case and I imagine the company would have already submitted an NDA had that happened. However, the parents from Duchenne Alliance trust him and that alone is good enough for me.
I don't think this is accurate at all. The CDC is on high alert and the WHO has become far more vocal about their concerns in the past week. The United States has taken notice.
They are currently neck-and-neck in the race to get their respective drugs to the market. Jacobus's drug is already being widely used by LEMS patients. If they can get their NDA submitted close to the same time as CPRX, the FDA will give them the nod because they have already been working with the FDA and because the patient advocate groups will come out in huge numbers in support of Jacobus. Jacobus currently sells their drug for next to nothing. CPRX will likely charge at least $65k/year. Assuming both drugs are equally effective, which company's drug would you support if you had to choose between the two?
1. Approval doesn't matter at this time. P3 results do.
2. Odds heavily favor positive P3 results are positive. When that happens, $3.50 should be easy.
3. That's more than a 50% return from here in under 1.5 months.
That's a pretty good risk/reward if you ask me.
If you want to argue the actual approval, you'd have merit. I personally believe Jacobus gets approved first. But that doesn't matter in the short term since it's a good year away or more.
In other words, your bash is rather weak. But I imagine you know that.
Even if Ebola wasn't in the forefront, SRPT is undervalued at its current price, given the huge catalyts remaining this year, some of which could move the stock significantly.
Dear tred, if the Ebola scare continues to get out of hand, the gov't will step up and pay for drug supply. They've already done this for clinical testing and furthermore, have ultimately intended to build a stockpile of drugs found to work, so I'm not sure why you have such a hard time believing they'll pay now when the crisis is at hand. It's really mind boggling how you refuse to see this.
You'll be right if the Ebola crisis can remain contained in Africa (doubtful at the moment), but if not, you're going to be very wrong. The gov't isn't going to sit around and watch people die, particularly when it already has a history of paying for the R&D on Ebola drugs. It's common sense.
TKMR's drug is also going to be used, and if the frontrunner right now is ZMapp. There isn't going to be one drug of choice. Could you at least try to be objective instead of just pumping for the sake of pumping? It doesn't help the stock price and makes you as suspicious as bashers.